Short-Term Therapy with Peroxisome Proliferation-Activator Receptor-Agonist Wy-14,643 Protects Murine Fatty Liver Against Ischemia-Reperfusion Injury

Hepatology

Volumn 51, Issue 3, 2010, Pages 996-1006

  Teoh, Narci C ^a   Williams, Jacqueline ^a   Hartley, Jennifer ^a   Yu, Jun ^b   McCuskey, Robert S ^c   Farrell, Geoffrey C ^a  

^a CANBERRA HOSPITAL   (Australia)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AUTACOID; CYCLIN D1; CYCLINE; I KAPPA B ALPHA; IMMUNOREACTIVE INSULIN; INTERLEUKIN 12; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE P38; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PIRINIXIC ACID; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL CYCLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FATTY LIVER; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; ISCHEMIA; LIPID DIET; LIVER CELL; LIVER NECROSIS; LIVER PROTECTION; LIVER SINUSOID; MALE; MICROCIRCULATION; MICROSCOPY; MICROVASCULARIZATION; MICROVASCULATURE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REPERFUSION; REPERFUSION INJURY; SHORT COURSE THERAPY;

ANIMALS; FATTY LIVER; MICE; PEROXISOME PROLIFERATORS; PYRIMIDINES; REPERFUSION INJURY; TIME FACTORS;

EID: 77950600111     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.23420     Document Type: Article

References (46)

1. Todo S, DemetrisAJ, MakowkaL, Teperman L, PodestaL, Shaver T, etal. Primary non-function of hepatic allografts with pre-exisiting fatty infiltration. Transplantation 1989;47:903-905.
2. Strasberg SM, Howard TK, Molmenti EP, Hertl M. Selecting the donor liver: risk factors for poor function after orthotopic liver transplantation. HEPATOLOGY 1994;20:829-838.
3. Trevisani F, Colantonit A, Caraceni P, Van Thiel DH. The use of donor fatty liver for transplantation: a challenge or quagmire? J Hepatol 1996; 22:114-121.
4. Alwayn IPJ, Porte RJ. How to make steatotic livers suitable for transplantation. Liver Transplantation 2007;13:480-482.
5. Busuttil RW, Tanaka K. The utility of marginal donors in liver transplantation. Liver Transpl 2003;9:651-663.
6. Ploeg RJ, DAlessandro AM, Knechtle SJ, Stegall MD, Pirsch JD, Hoffmann RM, et al. Risk factors for primary dysfunction after liver transplantation\a multi-variate analysis. Transplantation 1993;55:807-813.
7. Imber CJ, St Peter SD, Lopez I. Current practice regarding the use of fatty livers: a trans-Atlantic survey. Liver Transpl 2002;8:545-549.
8. Selzner M, Clavien PA. Fatty liver in liver transplantation and surgery. Semin Liver Dis 2001;21:105-113.
9. Arsov T, Larter CZ, Nolan CJ, Petrovsky N, Goodnow CC, Teoh NC, et al. Adaptive failure to high-fat diet characterizes steatohepatitis in Alms1 mutant mice. Biochem Biophys Res Commun 2006;342:1152-1159.
10. Ip E, Farrell G, Hall P, Robertson G, Leclercq I. Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice. HEPATOLOGY 2004;39:1286-1296
11. Teoh NC, Ito Y, Field J, Bethea NW, Amr A, McCuskey MK, et al. Diannexin, a novel Annexin V homodimer, provides prolonged protection against hepatic ischemia reperfusion injury in mice. Gastroenterology 2007;133:632-646.
12. Teoh N, de la Pena A, Farrell GC. Hepatic ischemic preconditioning in mice is associated with activation of NF-KB, p38 kinase and cell cycle entry. HEPATOLOGY 2002;36:94-102.
13. LeeuwenbergJF, Smeets EF,Neefjes JJ, Shaffer MA, CinekT, Jeunhomme TM, et al. E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro. Immunology 1991;77:543-549.
14. Matheny HE, DeemTL, Cook-Mills JM. Lymphocyte migration through mmonolayers of endothelial cell lines involves VCAM-1 signaling via endothelial cell NADPH oxidase. J Immunol 2000;164:6550-6559.
15. Woods CG, Burns AM, Bradford BU, Ross PK, Kosyk O, SwenbergJA, et al. Wy-14,643 induced cell proliferation and oxidative stress in mouse liver are independent of NADPH oxidase. Toxicol Sci 2007;98:366-374.
16. Hays T, Rusyn I, Burns AM, Kennett MJ, Ward JM, Gonzalez FJ, et al. Role of peroxisome proliferator-actovated receptor alpha (PPARalpha) in benzafibrate-induced hepatocarcinogenesis and cholestasis. Carcinogenesis 2005;26:219-227.
17. Teoh N, Farrell G. Hepatic ischemia reperfusion injury. Pathogenic mechanisms and basis for protection. J Gastroenterol Hepatol 2003;18:891-902.
18. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. HEPATOLOGY 2006;42:S99-S112.
19. Koteish A, Diehl AM. Animal models of steatosis. Semin Liver Dis 2001; 21:89-104.
20. Larter CZ, Yeh MM. Animal models of NASH: getting both pathology and metabolic context right. J Gastroenterol Hepatol 2008;23:1635-1648.
21. Leclercq IA, Farrell GC, Sempoux C, dela Pena A, Horsmans Y Curcumin inhibits NF-kappaB activation and reduces the severity of experimental steatohepatitis in mice. J Hepatol 2004;41:926-934.
22. McCuskey RS, Ito Y, Robertson GR, Perry M, Farrell GC. Hepatic microvascular dysfunction during evolution of dietary steatohepatitis in mice. HEPATOLOGY 2004;40:386-393.
23. Baskin-Bey ES, Canbay A, Bronk SF, Werneburg N, Guicciardi ME, Nyberg SL, et al. Cathepsin B inactivation attenuates hepatocyte apoptosis and liver damage in steatotic livers after cold ischemia-warm reperfusion injury. Am J Physiol Gastrointest Liver Physiol 2005;288:G396-G402.
24. Arsov T, Silva DG, O'Bryan MK, Sainsbury A, Lee NJ, Kennedy C, et al. Fat aussie\a new Alstrom syndrome mouse showing a critical role for Alms1 in obesity, diabetes, and spermatogenesis. Mol Endocrinol 2006; 20:1610-1622.
25. Seifalian AM, Chidambaram V, Rolles K, Davidson BR. In vivo demonstration of impaired microcirculation in steatotic human liver grafts. Liver Transplantation and Surgery 1998;1:71-77.
26. Seifalian AM, Piasecki C, Agarwal A, Davidson BR. The effect of graded steatosis on flow in the hepatic parenchymal microcirculation. Transplantation 1999;68:780-784.
27. Sato N, Eguchi H, Inoue A, MatsumuraT, Kawano S, KamadaT. Hepatic microcirculation in Zucker fatty rats. Adv Exp Med Biol 1986;200:477-483.
28. Sun CK, Zhang XY, Zimmermann A, Davis G, Wheatley AM. Effect of ischemia-reperfusion injury on the microcirculation of the steatotic liver of the Zucker rat. Transplantation 2001;72:1625-1631.
29. Farrell GC, Teoh NC, McCuskey RS. The hepatic microcirculation in fatty liver disease. Anat Rec 2008;291:684-692.
30. Teramoto K, BowersJL, Kruskal JB, Clouse ME. Hepatic microcirculatory changes after reperfusion in fatty and normal liver transplantation in the rat. Transplantation 1993;56:1076-1082.
31. Ito Y, Abril ER, Bethea NW, McCuskey MK, McCuskey RS. Dietary steatotic liver attenuates acetaminophen hepatotoxicity in mice. Microcirculation 2006;13:19-27.
32. Schmeding M, Hunold G, Ariyakhagorn V, Rademacher S, Boas-Knoop S, Lippert S, et al. Erythropoeitin reduces ischemia reperfusion injury after liver transplantation in rats. Transpl Int 2009;22:738-746.
33. Kato A, Graul-Layman A, Edwards MJ, Lentsch AB. Promotion of hepatic ischemia/reperfusion injury by IL-12 is independent of STAT4. Transpl 2002;73:1142-11115
34. Teoh N, Field J, Sutton J, Farrell G. Dual role of tumor necrosis factor-a in hepatic ischemia reperfusion injury: studies in TNF-a knockout mice. HEPATOLOGY 2004;39:412-421.
35. Taub R. Hepatoprotection via the IL6/STAT3 pathway. J Clin Invest 2003;112:978-980.
36. Teoh NC, Field J, Farrell GC. Interleukin-6 is a key mediator of the hepatoprotective and pro-proliferative effects of ischemic preconditioning in mice. J Hepatol 2006;45:20-27.
37. Hong F, Radaeva Sm Pan HN, Tian Z, Veech R, Gao B. Interleukin-6 alleviates hepatic steatosis and ischemia/reperfusion injury in mice with fatty liver disease. HEPATOLOGY 2004;40:933-941.
38. Palmer CN, Hsu MH, Griffin KJ, Raucy JL, Johnson EF. Peroxisome proliferator activated receptor-alpha expression in human liver. Mol Pharmacol 1998;53:14-22.
39. Bulhak AA, Jung C, Ö stenson C-G, Lundberg J, Sjöquist P-O, Pernow J. PPAR-a activation protects the type 2 diabetic myocardium against isch-emia-reperfusion injury: involvement of the PI3-kinase/Akt and NO pathway. Am J Physiol Heart Circ Physiol 2009;296:H719-H727.
40. Lovett-Racke AE, Hussain RZ, Northrop S, Choy J, Rocchini A, Matthes L, et al. Peroxisome proliferator-activated alpha agonists as therapy for autoimmune disease. J Immunol 2004;172:5790-5798.
41. Rusyn I, Asakura S, Pachkowski B, Bradford BU, Denissenko MF, Peters J, et al. Expression of base excision DNA repair genes is a sensitive biomarker for in vivo detection of chemical-induced chronic oxidative stress: identification of the molecular marker source of radicals responsible for DNA damage by per-oxisome proliferators. Cancer Res 2004;64:1050-1057.
42. Li Y, Leung LK, Glauert HP, Spear BT. Treatment of rats with the perox-isome proliferator ciprofibrate results in increased liver NF-kappa B activity. Carcinogenesis 1996;17:2305-2309.
43. Rusyn I, Yamashina S, Segal BH, Schoonhoven R, Holland SM, Cattley RC, et al. Oxidants from nicotinamide adenine dinucleotide phosphate oxidase are involved in triggering cell proliferation in the liver due to peroxisome proliferators. Cancer Res 2000;60:4798-4803.
44. Ng KK, Lo CM. Liver transplantation in Asia: past, present and future. Annals Acad Med 2009;38:322-331.
45. Lee SG. Asian contribution to living donor liver transplantation. J Gastro-enterol Hepatol 2006;21:572-574.
46. Pomfret EA, Sung RS, Allan J, Kinkhabwala M, Melancon JK, Roberts JP. Solving the organ shortage crisis: the Seventh Annual American Society of Transplant Surgeons' State-of-the-Art Winter Symposium. Am J Transpl 2008;8:745-752.